Literature DB >> 18359097

Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules.

Zhujun Ao1, Ami Patel, Kaylie Tran, Xinying He, Keith Fowke, Kevin Coombs, Darwyn Kobasa, Gary Kobinger, Xiaojian Yao.   

Abstract

In this study, we have generated and characterized an avian influenza H5N1 hemagglutinin (HA), neuraminidase (NA) and M2 ion channel pseudotyped HIV-based vector system (HaNaM-pseudotyped HIV vector). The cleavage site of the HA protein was modified to necessitate trypsin-dependent maturation of the glycoprotein. HA, NA and M2 were efficiently incorporated in HIV vector particles which could transduce different cell lines in a trypsin-dependent manner. Results also showed that the presence of avian influenza M2 and NA proteins maximized both vector production and transduction and that transduction was highly sensitive to the specific NA inhibitor oseltamivir (Tamiflu). H5N1 HaNaM-pseudotyped HIV vector system was also adapted for cell-based high throughput screening of drug candidates against influenza virus infection, and its high sensitivity to the specific oseltamivir validates its potential utility in the identification of new influenza inhibitors. Overall, the trypsin-dependent H5N1-pseudotyped HIV vector can mimic avian influenza virus infection processes with sufficient precision to allow for the identification of new antivirals and to study avian influenza virus biology in a lower biosafety level laboratory environment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359097      PMCID: PMC5123875          DOI: 10.1016/j.antiviral.2008.02.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  19 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.

Authors:  T McKay; M Patel; R J Pickles; L G Johnson; J C Olsen
Journal:  Gene Ther       Date:  2006-04       Impact factor: 5.250

3.  Containing pandemic influenza at the source.

Authors:  Ira M Longini; Azhar Nizam; Shufu Xu; Kumnuan Ungchusak; Wanna Hanshaoworakul; Derek A T Cummings; M Elizabeth Halloran
Journal:  Science       Date:  2005-08-03       Impact factor: 47.728

4.  Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.

Authors:  Chung-Lam Cheung; Jane M Rayner; Gavin J D Smith; Pui Wang; T S P Naipospos; Jinxia Zhang; Kwok-Yung Yuen; Robert G Webster; J S Malik Peiris; Yi Guan; Honglin Chen
Journal:  J Infect Dis       Date:  2006-05-09       Impact factor: 5.226

5.  Roles of neuraminidase in the initial stage of influenza virus infection.

Authors:  Masanobu Ohuchi; Naoko Asaoka; Tatsuya Sakai; Reiko Ohuchi
Journal:  Microbes Infect       Date:  2006-02-08       Impact factor: 2.700

6.  Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.

Authors:  S Li; C Liu; A Klimov; K Subbarao; M L Perdue; D Mo; Y Ji; L Woods; S Hietala; M Bryant
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

7.  Avian flu: isolation of drug-resistant H5N1 virus.

Authors:  Q Mai Le; Maki Kiso; Kazuhiko Someya; Yuko T Sakai; T Hien Nguyen; Khan H L Nguyen; N Dinh Pham; Ha H Ngyen; Shinya Yamada; Yukiko Muramoto; Taisuke Horimoto; Ayato Takada; Hideo Goto; Takashi Suzuki; Yasuo Suzuki; Yoshihiro Kawaoka
Journal:  Nature       Date:  2005-10-20       Impact factor: 49.962

8.  Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication.

Authors:  Zhujun Ao; Guanyou Huang; Han Yao; Zaikun Xu; Meaghan Labine; Alan W Cochrane; Xiaojian Yao
Journal:  J Biol Chem       Date:  2007-03-14       Impact factor: 5.157

9.  Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses.

Authors:  Judit Szécsi; Bertrand Boson; Per Johnsson; Pia Dupeyrot-Lacas; Mikhail Matrosovich; Hans-Dieter Klenk; David Klatzmann; Viktor Volchkov; François-Loïc Cosset
Journal:  Virol J       Date:  2006-09-03       Impact factor: 4.099

Review 10.  The molecular biology of influenza virus pathogenicity.

Authors:  H D Klenk; R Rott
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

View more
  14 in total

1.  Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies.

Authors:  Luis Martínez-Sobrido; Richard Cadagan; John Steel; Christopher F Basler; Peter Palese; Thomas M Moran; Adolfo García-Sastre
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

Review 2.  New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions.

Authors:  Grant Beyleveld; Kris M White; Juan Ayllon; Megan L Shaw
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

3.  Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics.

Authors:  Kin Kui Lai; Nam Nam Cheung; Fang Yang; Jun Dai; Li Liu; Zhiwei Chen; Kong Hung Sze; Honglin Chen; Kwok-Yung Yuen; Richard Yi Tsun Kao
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

4.  A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model.

Authors:  Ami Patel; Suresh Tikoo; Gary Kobinger
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

Review 5.  Pseudotype-based neutralization assays for influenza: a systematic analysis.

Authors:  George William Carnell; Francesca Ferrara; Keith Grehan; Craig Peter Thompson; Nigel James Temperton
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

6.  Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.

Authors:  Gary Wong; Xiangguo Qiu; Hideki Ebihara; Heinz Feldmann; Gary P Kobinger
Journal:  J Infect Dis       Date:  2015-05-28       Impact factor: 5.226

7.  HIV-1 envelope glycoprotein stimulates viral transcription and increases the infectivity of the progeny virus through the manipulation of cellular machinery.

Authors:  Xiaozhuo Ran; Zhujun Ao; Adriana Trajtman; Wayne Xu; Gary Kobinger; Yoav Keynan; Xiaojian Yao
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

8.  Zikavirus prME Envelope Pseudotyped Human Immunodeficiency Virus Type-1 as a Novel Tool for Glioblastoma-Directed Virotherapy.

Authors:  Maibritt Kretschmer; Patrycja Kadlubowska; Daniel Hoffmann; Birco Schwalbe; Heidi Auerswald; Michael Schreiber
Journal:  Cancers (Basel)       Date:  2020-04-18       Impact factor: 6.639

9.  A single residue substitution in the receptor-binding domain of H5N1 hemagglutinin is critical for packaging into pseudotyped lentiviral particles.

Authors:  Dong-Jiang Tang; Yuen-Man Lam; Yu-Lam Siu; Chi-Hong Lam; Shui-Ling Chu; J S Malik Peiris; Philippe Buchy; Béatrice Nal; Roberto Bruzzone
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

Review 10.  Current status on the development of pseudoviruses for enveloped viruses.

Authors:  Qianqian Li; Qiang Liu; Weijin Huang; Xuguang Li; Youchun Wang
Journal:  Rev Med Virol       Date:  2017-12-07       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.